News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rheonix, Inc. Workshop to Address Challenges of Implementing Personalized Medicine



7/15/2013 10:20:32 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

July 15, 2013 -- ITHACA, N.Y. – Widespread implementation of personalized medicine will depend upon identification of clinically relevant biomarkers, cost-effective methods to detect them and a reimbursement strategy that will meet the needs of all stakeholders.

These will be a few of the points raised during a workshop entitled “Implementing Effective and Reimbursable Personalized Medicine” at the upcoming joint annual meeting of the American Association for Clinical Chemistry (AACC) and the American Society for Clinical Laboratory Science (ASCLS). Molecular diagnostics company Rheonix, Inc. will host the workshop, with the goal of addressing many of the varied challenges facing the widespread adoption of personalized medicine.

Richard A. Montagna, Ph.D., senior vice president for scientific affairs at Rheonix, will outline these issues in his presentation, “Technical and Reimbursement Challenges of Personalized Medicine.” He will be joined by Dr. Saeed Jortani, associate professor of pathology and laboratory medicine at the University of Louisville School of Medicine, whose talk, “Pharmacogenomics of Pain Management Drugs,” will provide valuable insight into the practical use of genetic data to more effectively manage and treat pain.

The insight gained from this workshop will provide participants with useful information regarding the identification of clinically relevant biomarkers, their utilization in management of drug therapies, as well as the regulatory and reimbursement hurdles that must be overcome in order to implement widespread adoption.

“In order to reduce health care costs, it is imperative that diagnostic companies, health care professionals, regulatory bodies and payers work together to assure that the benefits of molecular diagnostic technologies can be realized for a broad spectrum of real-life diseases facing patients,” Montagna said. “Furthermore, the power of pharmacogenomics can reduce the cost of health care by assuring that the right drug is given to the right person at the right time, while at the same time avoiding the potential of costly adverse events.”

Montagna, based at the Grand Island, N.Y., location of Rheonix, has more than 30 years of leadership experience and has managed the commercialization of more than 40 biotechnology products, including FDA-regulated diagnostics. He has published 40 scientific papers and holds a number of patents in the biosensor area and is an adjunct professor in the department of biological and environmental engineering at Cornell University. Jortani’s training and experience is in toxicology, clinical chemistry, proteomics and pharmacogenomics. He is a board-certified clinical chemist and a practicing toxicologist, with research interests in proteomics, detection and measurement of drugs, therapeutics and poisons, and the use of pharmacogenomics in pain management and postmortem investigations. He serves on several national organizations in the area of laboratory medicine and on the editorial boards of several scientific journals.

The joint conference is being held in Houston from July 28 through August 1. The workshop will take place on July 30 at 7:00 am in Grand Ballroom D of the Hilton Americas Houston. Rheonix will be exhibiting in booth number 5005.

About Rheonix: Rheonix Inc. is committed to improving standards of care by making molecular diagnostics available to more people, in more places, more often. Rheonix, through experienced leadership and creative vision, has developed the EncompassMDx™ platform, a highly customizable technology with unmatched versatility and affordability. The platform performs fully automated, complex molecular assays in an easy-to-use and economical format on the Rheonix CARD® cartridge. With both the Rheonix CARD and EncompassMDx family of products, Rheonix is well-positioned to penetrate key molecular diagnostic market sectors, from reference labs through point-of-care and everywhere in between. For more information, visit www.rheonix.com.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES